A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions

2019 ◽  
Vol 123 (4) ◽  
pp. 394-397 ◽  
Author(s):  
Semra Demir ◽  
Asli Gelincik ◽  
Raif Coskun ◽  
Gulkan Ozkan ◽  
Nazli Demir ◽  
...  
Keyword(s):  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity ◽  
Desensitization Protocol

scholarly journals Successful olaparib desensitization using a novel one-day protocol

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Rongbo Zhu ◽  
Stephen Welch ◽  
Hannah Roberts
Keyword(s):  
Adverse Reactions ◽  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity ◽  
Case Presentation ◽  
Tablet Form ◽  
Desensitization Protocol ◽  
Ige Mediated ◽  
Loss Of Tolerance

Abstract Background Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with olaparib. Case presentation We report a 58-year-old female with immediate, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day novel desensitization protocol to olaparib. Following desensitization, the patient was successfully transitioned from olaparib capsules to tablets with no loss of tolerance. Conclusions To our knowledge, this is the first reported case of successful olaparib desensitization using a novel 1-day desensitization protocol, and will contribute to drug allergy knowledge, in an area where robust data is lacking. This case demonstrates the important role for drug desensitization in patients with immediate hypersensitivity reactions to chemotherapeutic agents. Furthermore, as olaparib capsules are being phased out in favour of olaparib tablets, we provide a clear case that transitioning from capsule to tablet form did not cause a loss of tolerance.

scholarly journals Management and Successful Desensitization in a Patient with Abatacept-Induced Anaphylaxis

2021 ◽  
Vol 19 (1) ◽  
pp. 46-49
Author(s):  
Ferda Bilgir ◽  
Gökhan Kabadayı ◽  
Servet Akar
Keyword(s):  
T Cell Activation ◽  
Cell Activation ◽  
Biological Agents ◽  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Insufficient Response ◽  
Desensitization Protocol ◽  
To Receive

ABSTRACT Abatacept is a fusion protein that blocks T cell activation. It is used in a variety of conditions including organ transplantation, immune deficiency, and autoimmune diseases. Even though abatacept-induced adverse events are observed, hypersensitivity reactions are rare. Desensitization protocols that can be implemented in the case of hypersensitivity reactions are present in the literature for many biological agents. However, a desensitization protocol for abatacept has not yet been established. Our patient, who was started on one of the biological agents, abatacept, for rheumatoid arthritis due to insufficient response to disease- modifying antirheumatic drugs, developed immediate hypersensitivity reaction with the first dose. Since it was planned to continue the treatment, abatacept desensitization was performed. The rapid desensitization protocol performed with prior premedication was successful and the patient was able to receive subsequent doses of abatacept using the same protocol. Keywords: Abatacept, anaphylaxis, desensitization

A Practical and Successful Desensitization Protocol for Immediate Hypersensitivity Reactions to Iron Salts

2014 ◽  
Vol 165 (2) ◽  
pp. 100-103 ◽  
Author(s):  
Semra Demir ◽  
Muge Olgac ◽  
Derya Unal ◽  
Asli Gelincik ◽  
Bahauddin Colakoglu ◽  
...  
Keyword(s):  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity ◽  
Iron Salts ◽  
Desensitization Protocol

scholarly journals Immediate hypersensitivity reaction followed by successful oral desensitization to ursodiol

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Erika Yue Lee ◽  
Christine Song
Keyword(s):  
Hypersensitivity Reaction ◽  
Primary Biliary Cholangitis ◽  
Line Treatment ◽  
Second Line ◽  
Immediate Hypersensitivity ◽  
First Line ◽  
Case Presentation ◽  
Desensitization Protocol ◽  
First Line Treatment ◽  
Oral Desensitization

Abstract Background Immediate hypersensitivity reaction to ursodiol is rare and there is no previously published protocol on ursodiol desensitization. Case presentation A 59-year-old woman with primary biliary cholangitis (PBC) developed an immediate hypersensitivity reaction to ursodiol—the first-line treatment for PBC. When she switched to a second-line treatment, her PBC continued to progress. As such, she completed a novel 12-step desensitization protocol to oral ursodiol. She experienced recurrent pruritus after each dose following desensitization, which subsided after a month of being on daily ursodiol. Conclusion Immediate hypersensitivity reaction to ursodiol is uncommon. Our case demonstrated that this novel desensitization protocol to ursodiol could be safely implemented when alternative options are not available or have proven inferior in efficacy.

Delayed and immediate hypersensitivity reactions associated with the use of amalgam

BDJ ◽  
2000 ◽  
Vol 188 (2) ◽  
pp. 73-76 ◽  
Author(s):  
B McGivern ◽  
M Pemberton ◽  
E D Theaker ◽  
J A G Buchanan ◽  
M H Thornhill
Keyword(s):  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity

Immediate hypersensitivity reactions of the heart: Reduction of tachycardia and arrhythmias by the SRS-A antagonist FPL 55712

1980 ◽  
Vol 2 (2) ◽  
pp. 173-176 ◽  
Author(s):  
Roberto Levi ◽  
James A. Burke ◽  
Betsy A. Holland ◽  
Frank J. Green
Keyword(s):  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity

scholarly journals Safety Assessment of Hydrolyzed Wheat Protein and Hydrolyzed Wheat Gluten as Used in Cosmetics

2018 ◽  
Vol 37 (1_suppl) ◽  
pp. 55S-66S ◽  
Author(s):  
Christina Burnett ◽  
Wilma F. Bergfeld ◽  
Donald V. Belsito ◽  
Ronald A. Hill ◽  
Curtis D. Klaassen ◽  
...  
Keyword(s):  
Safety Assessment ◽  
Expert Panel ◽  
Average Molecular Weight ◽  
Wheat Gluten ◽  
Safety Data ◽  
Hypersensitivity Reactions ◽  
Wheat Protein ◽  
Laboratory Studies ◽  
Immediate Hypersensitivity

The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) reviewed the product use, formulation, and safety data on hydrolyzed wheat protein and hydrolyzed wheat gluten, which function as skin- and hair-conditioning agents. The Panel determined that data from clinical and laboratory studies were sufficient to demonstrate that these ingredients will not elicit type 1 immediate hypersensitivity reactions in sensitized individuals and will not induce sensitization when the polypeptide lengths of the hydrolysates do not exceed 30 amino acids. The Panel concluded that hydrolyzed wheat gluten and hydrolyzed wheat protein are safe for use in cosmetics when formulated to restrict peptides to an average molecular weight of 3,500 Da or less.

Sign in / Sign up

Export Citation Format

Share Document